Glucagon

• The POST-PRANDIAL HYPO-AVOID STUDY Low-Dose Glucagon and Automated Insulin Delivery for Prevention of Spontaneous Exercise-Induced Hypoglyc… Recruiting
  2025-523996-45-00 Phase IV 1 country Steno Diabetes Center Copenhagen
• Impact of Glucagon on Physical Capacity and Metabolism Recruiting
  2025-521835-35-00 Phase II 1 country Katholisches Klinikum Bochum gGmbH
• The effect of [18F]F-FAPI PET-CT on management in patients with potentially resectable biliary tract cancers: prospective multicenter study … Recruiting
  2023-507938-24-00 Phase III 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• Evaluation of PSMA-PET and mpMRI in high-risk prostate cancer – using histopathologic validation Recruiting
  2022-501892-14-00 Phase III 1 country Region Vasterbotten; Umea University
• A Phase I/II, Randomised, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokine… Ended
  2023-504215-32-00 Phase I/II 3 countries AstraZeneca AB
• Premixed glucagon/insulin solution for faster insulin absorption in Type 1 diabetes. Halted
  2023-510408-32-02 Phase II 1 country St. Olavs Hospital HF
• A weight loss study evaluating subcutaneous treatment withAZD9550 and AZD6234 in combination, against placebo or each of the drugs alone Ended
  2024-516176-15-00 Phase II 1 country AstraZeneca AB
• Glucagon enhanced insulin absorption in Diabetes Mellitus type 1 Ended
  2022-502455-57-01 Phase II 1 country St. Olavs Hospital HF
• A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Ended
  2022-500101-41-00 Phase IV 4 countries Eli Lilly Cork Limited

Showing 1–9 of 9 trials